<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03558412</url>
  </required_header>
  <id_info>
    <org_study_id>hnslblzlzx20171118</org_study_id>
    <nct_id>NCT03558412</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma</brief_title>
  <official_title>A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mingzhi Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhengzhou University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the safety, tolerability, and clinical effects of decitabine combined with
      Second-line chemotherapy regimens for patients with relapsed or refractory T-lymphoblastic
      lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open，investigator initial clinical trial with a single arm, aimed to
      evaluate the safety, tolerability, and efficacy of decitabine combined with Second-line
      chemotherapy regimens (CODOX-M/IVAC) in relapsed or refractory T-lymphoblastic lymphoma. A
      total of 40 patients are planned to be enrolled into the study. Patients with diagnosis of
      relapsed or refractory T-lymphoblastic lymphoma will be treated with decitabine plus
      CODOX-M/IVAC. The primary end point is responder rate (RR) and time to progression (TTP), and
      the secondary end points include overall survival (OS) and the median survival time (MST).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RR</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Responder Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TTP</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Time To Progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MST</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Median Survival Time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>T-lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine+CODOX-M/IVAC for patients with relapsed or refractory T-lymphoblastic lymphoma who used Hyper-CVAD or BFM-90 as first-line therapy:regimen A:CODOX-M:cyclophosphamide,epirubicin,vincristine,methotrexate.Regimen B :IVAC:ifosfamide,etoposide，cytarabine.Decitabine,10mg,ivgtt,used for 5 days before A+B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>CODOX-M/IVAC</intervention_name>
    <description>Given ivgtt</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Given ivgtt</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>5-Aza-2'-deoxycytidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age: 14~60 years; ECOG rate ≤ 2; expected survival &gt; 3 months;

          -  patients with T-lymphoblastic lymphoma diagnosed by histopathology detection;

          -  patients ever received chemotherapy and/or radiotherapy;and can not be transplanted
             hematopoietic stem cells;

          -  patients with no chemotherapy contraindications: hemoglobin ≥ 90 g/L, absolute
             neutrophil count ≥1.5 x 109/L, blood platelet ≥100 x 109/L, ALT and AST ≤ 2-fold upper
             normal limit, serum bilirubin ≤ 1.5-fold upper normal limit, serum creatinine ≤
             1.5-fold upper normal limit, serum albumin ≥ 30 g/L, normal serofibrinogen;

          -  at least one measurable nidus;

          -  no other severe diseases conflict with this project, cardiopulmonary function is
             basically normal;

          -  the urine or blood pregnancy test of women in childbearing age must be negative in 7
             days before follow-up visit;

          -  applicable for follow-up visit;

          -  no other antitumor adjoint therapy (including antitumor Chinese medicine,
             immunotherapy and biotherapy), but double phosphate anti-bone transfer therapy and
             other symptomatic treatment are acceptable;

          -  understanding this study and assigning informed consent.

        Exclusion Criteria:

          -  rejecting providing blood preparation;

          -  allergic to drug in this study and with metabolic block;

          -  rejecting adopting reliable contraceptive method in pregnancy or lactation period;

          -  uncontrolled internal medicine disease (including uncontrolled diabetes, severe
             incompetence cardiac, lung, liver and pancreas);

          -  with severe infection;

          -  with primary or secondary central nervous system tumor invasion;

          -  with immunotherapy or radiotherapy contraindication;

          -  ever suffered with malignant tumor;

          -  having peripheral nervous system disorder or dysphrenia;

          -  with no legal capacity, medical or ethical reasons affecting research proceeding;

          -  participating other clinical trials simultaneously;

          -  adopting other anti-tumor medicine excluding this research;

          -  the researchers considering it inappropriate to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingzhi zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingzhi zhang, Pro,Dr</last_name>
    <phone>13838565629</phone>
    <email>Mingzhi_zhang@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mingzhi zhang</last_name>
    <phone>13838565629</phone>
    <email>Mingzhi_zhang@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology Department of The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang, Pro,Dr</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Mingzhi Zhang, Pro,Drc</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 4, 2018</study_first_submitted>
  <study_first_submitted_qc>June 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>September 12, 2018</last_update_submitted>
  <last_update_submitted_qc>September 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Mingzhi Zhang</investigator_full_name>
    <investigator_title>The director of oncology department of the first affiliated hospital</investigator_title>
  </responsible_party>
  <keyword>Decitabine</keyword>
  <keyword>RR</keyword>
  <keyword>TTP</keyword>
  <keyword>OS</keyword>
  <keyword>MST</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

